SLS Sellas Life Sciences Group Inc
Company Analysis
Latest News
🟢 Sellas Life Sciences is trading 7.1% up today on unconfirmed REGAL 80th-event report
Sellas Life Sciences is trading 7.1% up at $14.70 after renewed attention around an unconfirmed report that the Phase 3 REGAL leukemia trial reached its 80th...
🔴 Sellas Life Sciences is trading 4.19% down today as unconfirmed 80th-event report prompts skepticism
Sellas Life Sciences is trading 4.19% down at $13.50 as investor skepticism grows around an unconfirmed report that the Phase 3 REGAL leukemia trial reached...
🟢 Sellas Life Sciences rises 5.2% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Sellas Life Sciences is trading 10.07% up today ahead of REGAL trial readout
Sellas Life Sciences is trading at $14.75, up 10.07%, as investors anticipate the approaching REGAL trial readout. - No new company-specific announcement was...
🟢 Sellas Life Sciences is trading 5.5% up today on continued REGAL readout interest
Sellas Life Sciences is trading 5.5% up at $14.14, with the gain appearing driven by trading activity and continued interest in the upcoming REGAL readout. -...
🔴 Sellas Life Sciences falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Goldman Sachs Adds to Its Sellas Bet With a Leukemia Trial Two Deaths From a Verdict — Is the Stock Pricing in Hope or Evidence?
Shares shifted sharply higher as Goldman Sachs disclosed it had quietly added to its position in Sellas Life Sciences just as the company's make-or-break...
🟢 Sellas Life Sciences is trading 8.9% up today after multiple institutions raised their stakes and Phase 3 REGAL trial nears final analysis
- Sellas Life Sciences is trading 8.9% up at $14.27 today, fueled by significant institutional buying and the nearing final analysis of its pivotal Phase 3...
Goldman Sachs boosts Sellas Life Sciences stake, nearing critical leukemia trial results
Goldman Sachs increased its investment in Sellas Life Sciences by acquiring 29,122 additional shares. This purchase raises the firm's total stake by 5.2% to...
🟢 Sellas Life Sciences is trading 4.08% up today as REGAL trial nears final-analysis procedures
Sellas Life Sciences is trading 4.08% up now at $12.25 as investors continued digesting its August 11 earnings release and clinical update. - Management...
🟢 Sellas Life Sciences is trading 8.15% up today after Q2 report and REGAL trial progress
On August 12, 2026, Sellas Life Sciences is trading at $11.93, +8.15% following its August 11 second-quarter report, which matched the $0.05 loss-per-share...
SELLAS Life Sciences met second quarter 2026 EPS estimates while advancing pivotal Phase 3 REGAL trial
SELLAS Life Sciences reported a net loss for the second quarter of 2026 that met analyst expectations, despite a significant increase in operating expenses...
🔴 Sellas Life Sciences is trading 4.08% down today ahead of August 11 earnings report
Sellas Life Sciences is trading now 4.08% down at $11.52 as investors await its August 11, 2026, earnings report. - No new company-specific announcement was...
Sellas Life Sciences Group Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Sellas Life Sciences is expected to report a Q2 2026 net loss of $0.05 per share on zero revenue, with the stock currently trading at $12.01 against an average...
Sellas Life Sciences Surges 10.8% on Trial Hopes and Fresh Institutional Buying — But Can a Single Data Readout Justify the Bet?
Shares of Sellas Life Sciences (SLS) jumped 10.8% to $11.09 on August 7, rebounding sharply from a late-July pullback, as investors piled in ahead of what may...
🟢 Sellas Life Sciences is trading 4.2% up today as REGAL trial optimism and institutional interest fuel rebound
Sellas Life Sciences is trading at $11.69 (up 4.2%) as its recent rebound extends following a strong move in the prior session. • Investors remain focused on...
🟢 Sellas Life Sciences is trading 10.8% up today on REGAL trial optimism and institutional interest
Sellas Life Sciences is trading 10.8% up today at $11.09, extending its recent rebound after last week’s pullback. • Bullish sentiment is being driven by...
🟢 Sellas Life Sciences is trading 5.9% up today on REGAL trial optimism and institutional interest
Sellas Life Sciences is trading at $10.60 (+5.9%) as the stock continues its recent upward trajectory fueled by positive clinical and funding narratives. •...
🟢 Sellas Life Sciences is trading 5.6% up today on strong cash runway and upcoming REGAL trial trigger
Sellas Life Sciences is trading 5.6% up today at $10.66 as investors refocus on the company's $138.3 million cash position and upcoming clinical milestones. •...
🔴 Sellas Life Sciences is trading 11.68% down today following earnings and 3D Medicines arbitration loss
Sellas Life Sciences is trading 11.68% down at $9.57 following its July 27 earnings update and a significant legal setback involving a lost binding arbitration...